Correvio has two marketed, in-hospital, cardiology products: BRINAVESSÂŽ (vernakalant HCl, IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTATÂŽ (tirofiban HCl), a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome (ACS). Correvio also commercializes ESMOCARDÂŽ and ESMOCARD LYOÂŽ (esmolol hydrochloride), a short-acting beta-blocker used to control rapid heart rate in a number of cardiovascular indications, including supraventricular tachycardia (SVT), on behalf of its partner AOP Orphan Pharma in select European markets.
Source
